Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Zanubrutinib achieved high response rate in del(17p) CLL cohort
Key clinical point: Zanubrutinib was well tolerated and had a high overall response rate in one the largest cohorts of patients with treatment-naive chromosome 17p-deletion chronic lymphocytic leukemia studied to date.
Major finding: With a median follow-up of 10 months, the overall response rate was 92.7%, with 95% remaining in response at 6 months.
Study details: Initial results from one cohort of the SEQUOIA (BGB-3111-304) trial involving 109 patients with treatment-naive 17p-deletion chronic lymphocytic leukemia.
Disclosures: The SEQUOIA study is sponsored by BeiGene. Dr. Tam reported disclosures related to Novartis, Pharmacyclics, AbbVie, BieGene, Janssen, and Roche.
Tam C et al. ASH 2019, Abstract 499.